Replies to post #5746 on Arbutus Biopharma Corporation (ABUS)

[Purple Wonder]

Is a nice deal for ABUS to get instant cash, then regain the royalty payments after the other company has recouped 30 mil.

Looking at Q2 revenues, they made $825k for the 3 months in licensing ALONE, TWICE how much they made the year prior for Q2. Also, up to 1.6 mil in licensing for the year, 2x more than same period last year. We are up to 3 mil in revenues for the year (first 6 months) to include non cash royalty revenue, up more than DOUBLE that of same time period last year.

We have nearly 84 million dollars in cash (45 million) and assets.

We lost .25 per share, down 50% from same period last year.

Summary= Revenues increasing, losses decreasing, and we have enough money to fund operations through mid 2022 NOW opposed to mid 2021 as stated in previous Q1 statement.

We are heading in the right direction for a company to become profitable. We are steadily adding licensing and royalty revenue streams as our patented technology is used and proven by more pharma companies. Future is very bright here. MRNA signs deal with Genovant, PPS is out of single dollar range immediately IMO. And based on what DD I have done, it is a matter of when not if.